Active, not recruitingPhase 2NCT04668300

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Studying Angiosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Neeta Somaiah
M.D. Anderson Cancer Center
Intervention
Durvalumab(biological)
Enrollment
75 enrolled
Eligibility
12 years · All sexes
Timeline
2020 – 2026

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04668300 on ClinicalTrials.gov

Other trials for Angiosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Angiosarcoma →

← Back to all trials